Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1988 1
1992 2
1993 1
1995 1
1997 1
1998 3
1999 1
2000 1
2001 1
2002 2
2003 3
2004 6
2007 2
2008 3
2009 1
2010 1
2011 2
2012 1
2013 1
2014 3
2015 5
2016 1
2017 1
2019 3
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases.
Lora-Tamayo J, Palom X, Sarrá J, Gasch O, Isern V, Fernández de Sevilla A, Pujol R. Lora-Tamayo J, et al. Among authors: fernandez de sevilla a. Clin Lymphoma Myeloma. 2008 Dec;8(6):363-9. doi: 10.3816/CLM.2008.n.054. Clin Lymphoma Myeloma. 2008. PMID: 19064403 Review.
Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution.
Salas MQ, Climent F, Tapia G, DomingoDomènech E, Mercadal S, Oliveira AC, Aguilera C, Olga G, Moreno Velázquez M, Andrade-Campos M, Encuentra M, Fernández de Sevilla A, Sureda A, Sancho JM, González-Barca E. Salas MQ, et al. Among authors: fernandez de sevilla a. Biomarkers. 2020 Feb;25(1):69-75. doi: 10.1080/1354750X.2019.1691656. Epub 2019 Nov 21. Biomarkers. 2020. PMID: 31752540
Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.
López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, González M, Ribera JM, Brunet S, García-Conde J, Fernández de Sevilla A, Bosch F, Montserrat E. López-Guillermo A, et al. Among authors: fernandez de sevilla a. Ann Oncol. 1998 Aug;9(8):849-55. doi: 10.1023/a:1008418727472. Ann Oncol. 1998. PMID: 9789607 Free article. Review.
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ, Mercadal S, Domingo Domenech E, Oliveira AC, Encuentra M, Climent F, Andrade Campos M, Aguilera C, Fernández de Sevilla A, Sureda A, González-Barca E. Salas MQ, et al. Among authors: fernandez de sevilla a. Leuk Lymphoma. 2020 Mar;61(3):575-581. doi: 10.1080/10428194.2019.1683733. Epub 2019 Nov 5. Leuk Lymphoma. 2020. PMID: 31684781
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, Carreras E, León A, Arranz R, Fernández de Sevilla A, Zuazu J, García-Laraña J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E. Rodríguez J, et al. Among authors: fernandez de sevilla a. Ann Oncol. 2003 Dec;14(12):1768-75. doi: 10.1093/annonc/mdg459. Ann Oncol. 2003. PMID: 14630683 Free article. Clinical Trial.
Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience.
Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, Sierra J, Gandarillas M, Perez-Simon JA, Zuazu J, Lopez-Guillermo A, Sureda A, Carreras E, Garcia-Laraña J, Marin J, Garcia JC, Fernandez De Sevilla A, Rifon J, Varela R, Jarque I, Albo C, Leon A, SanMiguel J, Conde E. Rodriguez J, et al. Among authors: fernandez de sevilla a. Ann Oncol. 2004 Oct;15(10):1504-9. doi: 10.1093/annonc/mdh391. Ann Oncol. 2004. PMID: 15367411 Free article.
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC. Marcé S, et al. Among authors: fernandez de sevilla a. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22. Med Clin (Barc). 2013. PMID: 23433665
44 results